Table 1.
Clinicopathological characteristics of the study population
| Parameter | No. | % (range) |
|---|---|---|
| Sample size | 194 | |
| Median length of follow-up (months) | 193 | 67.1 (14.8 - 302.8) |
| Median age (years) | 51 (27 - 84) | |
| <40 | 21 | 11% |
| 40-49 | 66 | 34% |
| 50-59 | 50 | 26% |
| ≥60 | 57 | 29% |
| Menopausal status | ||
| Premenopausal | 75 | 39% |
| Perimenopausal | 8 | 4% |
| Postmenopausal | 96 | 49% |
| Not reported | 15 | 8% |
| Tissue source | ||
| Primary breast | 187 | 96% |
| Other* | 7 | 4% |
| Tumor histology | ||
| Invasive ductal carcinoma | 172 | 89% |
| Invasive lobular carcinoma | 14 | 7% |
| Other histologic type** | 8 | 4% |
| Median tumor size (cm) | 185 | 2.1 (0.4 - 14) |
| Not reported | 9 | |
| Tumor grade | ||
| Grade 1 (well) | 17 | 9% |
| Grade 2 (moderate) | 49 | 25% |
| Grade 3 (poor) | 93 | 48% |
| Not reported | 35 | 18% |
| Stage at initial diagnosis | ||
| I | 46 | 24% |
| II | 91 | 47% |
| III | 40 | 21% |
| IV | 13 | 7% |
| Not reported | 4 | 2% |
| Nodal status at initial diagnosis | ||
| Node positive | 89 | 46% |
| Node negative | 66 | 34% |
| Not reported | 39 | 20% |
| HER2 status (reported) | ||
| Positive | 83 | 43% |
| Negative | 110 | 57% |
| Equivocal | 1 | 1% |
| HER2 IHC (reported) | ||
| 3+ | 73 | 38% |
| 2+ | 30 | 16% |
| IHC 2+/FISH positive | 2 | 7% |
| IHC 2+/FISH negative | 18 | 60% |
| IHC 2+/FISH not reported | 10 | 33% |
| 1+ | 32 | 17% |
| 0 | 56 | 29% |
| HER2 FISH (reported) | ||
| Positive | 23 | 36% |
| Negative | 41 | 64% |
| Hormone receptor (ER/PR) status | ||
| Positive | 141 | 73% |
| Negative | 53 | 27% |
| ER and PR status | ||
| ER (+), PR (+) | 110 | 57% |
| ER (+), PR (−) | 30 | 15% |
| ER (−), PR (+) | 1 | 1% |
| ER (−), PR (−) | 53 | 27% |
| HER2 targeted therapy # | ||
| No | 174 | 90% |
| Yes | 20 | 10% |
*Other tissue sources: skin, supraclavicular, sentinental lymph node, axillary lymph node, ovary, lung, chest wall; **other histologic type: ‘invasive mammary’ (5), breast adenocarcinoma (1), infiltrating mucinous, adenocarcinoma (1), and metastatic carcinoma (1); #trastuzumab- and/or lapatinib-containing therapy. ER, estrogen receptor; FISH, fluorescence in situ hybridization; HER2, human epidermal growth factor receptor 2; IHC, immunohistochemistry; PR, progesterone receptor.